Stephen Clarke: Leading the Way at the ATOM Festival of Science...

Stephen Clarke, our Principal at Cherwell College Oxford, is not only a distinguished leader and former British diplomat, but also a passionate advocate for science and education. As the Chairman of ATOM Festival of Science & Technology, Stephen plays a pivotal role in bringing world-class scientific discussions and innovations to the heart of Abingdon. Stephen’s leadership ensures that the festival remains dynamic, inclusive, and engaging for people of all ages.

Intertronics: Driving Innovation in Adhesives and Assembly Solutions

For over four decades, Intertronics has been at the forefront of providing high-performance adhesives, coatings, sealants, and application equipment to industries that demand precision and reliability. From electronics and medical devices to automotive and aerospace, Intertronics’ expertise ensures that manufacturers can optimise their bonding and assembly processes with cutting-edge solutions.

Owen Mumford: 70 Years of Innovation in Healthcare

Owen Mumford has been at the forefront of medical device innovation for over 70 years, pioneering solutions that enhance patient care and improve healthcare outcomes worldwide. Established in 1952 by Ivan Owen and John Mumford, the company has grown into a global leader in medical device design and manufacturing, with a commitment to quality, sustainability, and patient-centred innovation.

Intertronics

INTERTRONICS supplies adhesives, coatings, sealants and equipment to customers with high technology, high-performance assembly applications. Our customers are manufacturers in industries such as electronics, medical devices, plastics, optical, automotive, energy, defence and aerospace.

Strengthening the UK clinical research environment

A recent ABPI report highlighted a decline in UK clinical trials. Improving the UK ecosystem for clinical research will involve a range of measures, and we look forward to publication of the O’Shaughnessy review. This sits alongside an ongoing substantial upgrade to UK clinical trials legislation and guidance, that forms the focus of this article.